Rizatriptan Benzoate Tablet
Product Images NDC 50090-3343

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 50090-3343). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903343)

FDA Label Image

Rizatriptan Fig 1

This is a chart displaying the percentages of response probability for three different treatments over a 10-hour period post-dose. The treatments are placebo, RIZATRIPTAN BENZOATE 5 mg, and RIZATRIPTAN BENZOATE 10 mg. The probability of response is highest with RIZATRIPTAN BENZOATE 5 mg and 10 mg, while the response probability for the placebo is consistently 0%. The chart also shows that the highest probability of response occurs at the 2-hour mark post-dose for both RIZATRIPTAN BENZOATE treatments.*

FDA Label Image

Rizatriptan Fig 2

This is a graph displaying the estimated probability of remedication or rescue after the administration of Rizatriptan Benzoate at 5mg and 10mg doses. The graph shows the percentage of patients requiring remedication or rescue over a 24-hour post-dose period.*

FDA Label Image

Rizatriptan Fig 5

FDA Label Image

Rizatriptan Structure

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.